ProQR Therapeutics (NASDAQ: PRQR) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.


This table compares ProQR Therapeutics and Dicerna Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics N/A -97.68% -75.50%
Dicerna Pharmaceuticals -5,895.26% -293.25% -87.25%

Analyst Ratings

This is a summary of current ratings and recommmendations for ProQR Therapeutics and Dicerna Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics 0 1 3 0 2.75
Dicerna Pharmaceuticals 0 1 3 0 2.75

ProQR Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 700.00%. Dicerna Pharmaceuticals has a consensus price target of $7.00, indicating a potential downside of 7.41%. Given ProQR Therapeutics’ higher possible upside, research analysts plainly believe ProQR Therapeutics is more favorable than Dicerna Pharmaceuticals.

Volatility & Risk

ProQR Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500.

Valuation & Earnings

This table compares ProQR Therapeutics and Dicerna Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics $130,000.00 735.23 -$43.27 million ($1.90) -1.58
Dicerna Pharmaceuticals $290,000.00 543.54 -$59.51 million ($3.43) -2.20

ProQR Therapeutics has higher earnings, but lower revenue than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

31.6% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 54.4% of Dicerna Pharmaceuticals shares are held by institutional investors. 29.4% of Dicerna Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


ProQR Therapeutics beats Dicerna Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide, for the treatment of Leber’s congenital amaurosis (LCA), and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with's FREE daily email newsletter.